Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Fourth Quarter Revenue: $85.8 million, a 43% year-over-year growth. Full Year Revenue: $291.8 million, a 44% increase compared to 2024. Recorlev Revenue: $45.3 million in Q4 and $139.3 million for the full year, over 100% growth year-over-year. Gvoke Revenue: $24.6 million in Q4 and $94.1 million for the full year. Keveyis Revenue: $12.8 million in Q4 and $47.6 million for the full year. Gross Margin: 87% in Q4 and 85% for the full year. R&D Expenses: $7.9 million in Q4 and $31.2 million for the full year, a 22% increase year-over-year. SG&A Expenses: $47.5 million in Q4 and $182.4 million for the full year, a 12% increase year-over-year. Adjusted EBITDA: $25.1 million in Q4 and $59.4 million for the full year. Net Income: Achieved net income on a full-year basis for 2025. 2026 Revenue Guidance: Expected between $375 million and $390 million, over 30% growth at the midpoint. 2026 R&D Increase: Approximately $25 million
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Xeris Biopharma: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance [Yahoo! Finance]Yahoo! Finance
XERS
Earnings
- 3/2/26 - Beat
XERS
Sec Filings
- 3/2/26 - Form 144
- 3/2/26 - Form S-8
- 3/2/26 - Form 10-K
- XERS's page on the SEC website